Search Results

• • 17 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Risk of fatigue and hepatic and metabolic toxicities in patients with solid tumors treated with everolimus: a meta-analysis

  Authors:Omar Abdel-Rahman and Mona FouadFrom:Future Oncology (Vol. 11, Issue 1) Peer-Reviewed

  Jan. 20154,956 words Report 1650LAuthor(s): Omar Abdel-Rahman [*] aff1 , Mona Fouad aff2 KEYWORDS everolimus; fatigue; hyperglycemia; meta-analysis Everolimus is a rapamycin derivative that inhibits the mTOR pathway by acting on mTORC1 [1 ]....

• Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity

  Authors:Camillo Porta, Palma Giglione, Wanda Liguigli, and Chiara PaglinoFrom:Future Oncology (Vol. 11, Issue 1) Peer-Reviewed

  Jan. 20157,666 words Report 1960LAuthor(s): Camillo Porta [*] aff1 aff2 , Palma Giglione aff1 , Wanda Liguigli aff3 , Chiara Paglino aff1 aff2 KEYWORDS dovitinib; drug development; FGFR inhibitor; renal cell carcinoma; VEGFR inhibitor Agents...

• Ipilimumab in the treatment of prostate cancer

  Authors:Zachary Reese, Ali Straubhar, Sumanta K Pal, and Neeraj AgarwalFrom:Future Oncology (Vol. 11, Issue 1) Peer-Reviewed

  Jan. 20157,133 words Report 1570LAuthor(s): Zachary Reese aff1 , Ali Straubhar aff2 , Sumanta K Pal aff3 , Neeraj Agarwal [*] aff1 KEYWORDS CTLA-4; immunotherapy; ipilimumab; prostate cancer Prostate cancer is the most common noncutaneous...

• What is the future for cancer clinical trials?

  Author:Francesco PerroneFrom:Future Oncology (Vol. 11, Issue 1) Peer-Reviewed

  Jan. 20152,314 words Article 2150LAuthor(s): Francesco Perrone [*] KEYWORDS biomarkers; clinical trials; drug price; personalized medicine; precision medicine; sustainability Two important phenomena have been characterized in recent years in...

• Pertuzumab-induced cardiotoxicity: safety compared with trastuzumab

  Authors:Mehmet AN Sendur, Sercan Aksoy, and Kadri AltundagFrom:Future Oncology (Vol. 11, Issue 1) Peer-Reviewed

  Jan. 20151,974 words Report 2730LAuthor(s): Mehmet AN Sendur [*] aff1 , Sercan Aksoy aff2 , Kadri Altundag aff2 KEYWORDS breast cancer; HER2; pertuzumab; pertuzumab-induced cardiotoxicity; trastuzumab; trastuzumab-induced cardiotoxicity...

• Development of chronic myeloid leukaemia in patients treated with anti-VEGF therapies for clear cell renal cell cancer

  Authors:Anna M Czarnecka, Sylwia Oborska, Piotr Rzepecki, and Cezary SzczylikFrom:Future Oncology (Vol. 11, Issue 1) Peer-Reviewed

  Jan. 20156,791 words Report 1790LAuthor(s): Anna M Czarnecka [*] aff1 , Sylwia Oborska aff2 , Piotr Rzepecki aff2 , Cezary Szczylik aff1 KEYWORDS clear cell renal cell; CML; RCC; renal cell cancer; sorafenib; sunitinib; tyrosine kinase carcinoma...

• Breakthrough targeted therapeutic approaches to squamous cell carcinoma of the head and neck

  Authors:Alberto Mangano, Alessandro Mangano, Georgios D Lianos, Dimitrios H Roukos, Alberto Caprioglio, and Gianlorenzo DionigiFrom:Future Oncology (Vol. 11, Issue 1) Peer-Reviewed

  Jan. 20152,759 words Report 1810LAuthor(s): Alberto Mangano [*] aff1 , Alessandro Mangano aff2 , Georgios D Lianos aff3 , Dimitrios H Roukos aff3 , Alberto Caprioglio aff2 , Gianlorenzo Dionigi aff1 KEYWORDS head and neck squamous cell carcinoma;...

• Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma

  Authors:Peter Hersey and Kavitha GowrishankarFrom:Future Oncology (Vol. 11, Issue 1) Peer-Reviewed

  Jan. 20155,797 words Report 1800LAuthor(s): Peter Hersey [*] aff1 , Kavitha Gowrishankar aff1 KEYWORDS 1-year survival; melanoma; PD-L1; PD1 checkpoint inhibitors; PFS; response rates The treatment of metastatic melanoma has undergone rapid...

• The HELIOS trial protocol: a Phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia

  Authors:Michael Hallek, Neil E Kay, Anders Osterborg, Asher A Chanan-Khan, Michelle Mahler, Mariya Salman, et al.From:Future Oncology (Vol. 11, Issue 1) Peer-Reviewed

  Jan. 20155,910 words Report 1980LAuthor(s): Michael Hallek aff1 , Neil E Kay aff2 , Anders Osterborg aff3 , Asher A Chanan-Khan aff4 , Michelle Mahler aff5 , Mariya Salman aff5 , Ying Wan aff5 , Steven Sun aff5 , Sen Hong Zhuang aff5 , Angela Howes...

• Metastatic castration-resistant prostate cancer: time for innovation

  Authors:Marcello Tucci, Giorgio Vittorio Scagliotti, and Francesca VignaniFrom:Future Oncology (Vol. 11, Issue 1) Peer-Reviewed

  Jan. 201511,880 words Report 1650LAuthor(s): Marcello Tucci aff1 , Giorgio Vittorio Scagliotti [*] aff1 , Francesca Vignani aff1 KEYWORDS bone-targeting agents; castration-resistant prostate cancer; chemotherapy; endocrine therapy; immunotherapy...

• Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?

  Authors:Sebastiano Buti, Chiara Ciccarese, Daniele Zanoni, Matteo Santoni, Alessandra Modena, Francesca Maines, et al.From:Future Oncology (Vol. 11, Issue 1) Peer-Reviewed

  Jan. 201510,278 words Report 1930LAuthor(s): Sebastiano Buti aff1 , Chiara Ciccarese aff2 , Daniele Zanoni aff1 , Matteo Santoni aff3 , Alessandra Modena aff2 , Francesca Maines aff2 , Annalisa Gilli aff1 , Emilio Bria aff2 , Matteo Brunelli aff4 ,...

• The role of miRNAs in bone metastasis and their significance in the detection of bone metastasis: a review of the published data

  Authors:Qian Huang and Xuenong OuyangFrom:Future Oncology (Vol. 11, Issue 1) Peer-Reviewed

  Jan. 20158,088 words Report 1980LAuthor(s): Qian Huang aff1 , Xuenong Ouyang [*] aff1 aff2 aff3 aff4 KEYWORDS bone metastasis; bone metastatic microenvironment; clinical evidence; diagnostic value; miRNAs Bone is the most frequent site for...

• Pericytes: a double-edged sword in cancer therapy

  Authors:Mao-Bin Meng, Nicholas G Zaorsky, Lei Deng, Huan-Huan Wang, Jiang Chao, Lu-Jun Zhao, et al.From:Future Oncology (Vol. 11, Issue 1) Peer-Reviewed

  Jan. 20156,841 words Report 1770LAuthor(s): Mao-Bin Meng [*] aff1 , Nicholas G Zaorsky aff2 , Lei Deng aff3 aff4 , Huan-Huan Wang aff1 , Jiang Chao aff1 , Lu-Jun Zhao aff1 , Zhi-Yong Yuan aff1 , Wang Ping aff1 KEYWORDS anti-angiogenesis therapy;...

• Pathology, therapy and prognosis of papillary renal carcinoma

  Authors:Diana Silva Fernandes and Jose Manuel LopesFrom:Future Oncology (Vol. 11, Issue 1) Peer-Reviewed

  Jan. 20159,634 words Report 2810LAuthor(s): Diana Silva Fernandes [*] aff1 , José Manuel Lopes aff1 KEYWORDS chromosomal; epidemiology; genetic; immunohistochemical; morphology; papillary renal cell carcinoma; prognosis; treatment Epidemiology...

• What is the best strategy for targeting EGF receptors in non-small-cell lung cancer?

  Author:Robert PirkerFrom:Future Oncology (Vol. 11, Issue 1) Peer-Reviewed

  Jan. 201511,701 words Report 1840LAuthor(s): Robert Pirker [*] KEYWORDS advanced lung cancer; EGFR; monoclonal antibodies; targeted therapy; tyrosine kinase inhibitors Current American Society of Clinical Oncology (ASCO) clinical guidelines for...

• Neoadjuvant breast cancer treatment as a sensitive setting for trastuzumab biosimilar development and extrapolation

  Authors:Christian Jackisch, Frank A Scappaticci, Dominik Heinzmann, Fabio Bisordi, Thomas Schreitmuller, Gunter von Minckwitz, et al.From:Future Oncology (Vol. 11, Issue 1) Peer-Reviewed

  Jan. 20156,795 words Report 1690LAuthor(s): Christian Jackisch [*] aff1 , Frank A Scappaticci aff2 , Dominik Heinzmann aff3 , Fabio Bisordi aff3 , Thomas Schreitmüller aff3 , Gunter von Minckwitz aff4 , Javier Cortés aff5 KEYWORDS biosimilar;...

• Exceptional responders: in search of the science behind the miracle cancer cures

  Authors:Ishwaria Mohan Subbiah and Vivek SubbiahFrom:Future Oncology (Vol. 11, Issue 1) Peer-Reviewed

  Jan. 20152,516 words Report 1900LAuthor(s): Ishwaria Mohan Subbiah aff1 , Vivek Subbiah [*] aff2 aff3 KEYWORDS exceptional responder; genomics; next-generation sequencing; outlier responder; unusual responder "In solving a problem of this...